EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tailored Beta‐Lapachone Nanomedicines for Cancer‐Specific Therapy

Yaru Li, Meiyu Feng, Tao Guo, Zheng Wang, Yanjun Zhao iD

Advanced Healthcare Materials · 2023

DOI: 10.1002/adhm.202300349 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Yaru Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Tianjin Key Laboratory for Modern Drug Delivery and High Efficiency, and Collaborative Innovation Ce…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Naphthoquinones, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 155 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanotechnology shows the power to improve efficacy and reduce the adverse effects of anticancer agents. As a quinone‐containing compound, beta‐lapachone (LAP) is widely employed for targeted anticancer therapy under hypoxia. The principal mechanism of LAP‐mediated cytotoxicity is believed due to the continuous generation of reactive oxygen species with the aid of NAD(P)H: quinone oxidoreductase 1 (NQO1). The cancer selectivity of LAP relies on the difference between NQO1 expression in tumors and that in healthy organs. Despite this, the clinical translation of LAP faces the problem of narrow therapeutic window that is challenging for dose regimen design. Herein, the multifaceted anticancer mechanism of LAP is briefly introduced, the advance of nanocarriers for LAP delivery is reviewed, and the combinational delivery approaches to enhance LAP potency in recent years are summarized. The mechanisms by which nanosystems boost LAP efficacy, including tumor targeting, cellular uptake enhancement, controlled cargo release, enhanced Fenton or Fenton‐like reaction, and multidrug synergism, are also presented. The problems of LAP anticancer nanomedicines and the prospective solutions are discussed. The current review may help to unlock the potential of cancer‐specific LAP therapy and speed up its clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNaphthoquinonesNeoplasmsNanomedicineProspective StudiesCell Line, TumorNAD(P)H Dehydrogenase (Quinone)

Stichwörter der Autor:innen

NQO1beta-lapachonedrug deliveryhypoxiananomedicines

Substanzen

beta-lapachoneAntineoplastic AgentsNaphthoquinonesNAD(P)H Dehydrogenase (Quinone)

Autor:innen und Institutionen

  • School of Pharmaceutical Science and Technology, Tianjin Key Laboratory for Modern Drug Delivery and High Efficiency, and Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin University…
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, 300120, China.

ORCID-Profile: Yanjun Zhao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, Y., Feng, M., Guo, T., Wang, Z., & Zhao, Y. (2023). Tailored Beta‐Lapachone Nanomedicines for Cancer‐Specific Therapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202300349

Vancouver

Li Y, Feng M, Guo T, Wang Z, Zhao Y. Tailored Beta‐Lapachone Nanomedicines for Cancer‐Specific Therapy. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202300349

BibTeX
@article{Li2023,
  author = {Li, Yaru and Feng, Meiyu and Guo, Tao and Wang, Zheng and Zhao, Yanjun},
  title = {Tailored Beta‐Lapachone Nanomedicines for Cancer‐Specific Therapy},
  journal = {Advanced Healthcare Materials},
  year = {2023},
  doi = {10.1002/adhm.202300349}
}
Kostenlos starten →